{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:48:49Z","timestamp":1792057729614,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["PX2022007"],"award-info":[{"award-number":["PX2022007"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022815","name":"Beijing Tongren Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071000"],"award-info":[{"award-number":["82071000"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xops.2026.101334","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:04:18Z","timestamp":1784790258000},"page":"101334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stepwise Increase in Concentrations of Atropine Treatment for Myopia Control Study"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-6743","authenticated-orcid":false,"given":"Shifei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1789-2532","authenticated-orcid":false,"given":"Wenzai","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6269-8015","authenticated-orcid":false,"given":"Weiling","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhining","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8933-4482","authenticated-orcid":false,"given":"Ningli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101334_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","article-title":"Myopia","volume":"6","author":"Baird","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.xops.2026.101334_bib2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/APO.0000000000000236","article-title":"Epidemiology of myopia","volume":"5","author":"Wu","year":"2016","journal-title":"Asia Pac J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib3","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1167\/iovs.18-24363","article-title":"Refractive errors in university students in central China: the Anyang University Students Eye Study","volume":"59","author":"Wei","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101334_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications","volume":"25","author":"Saw","year":"2005","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.xops.2026.101334_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/iovs.62.5.2","article-title":"IMI impact of myopia","volume":"62","author":"Sankaridurg","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101334_bib7","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/eye.2008.225","article-title":"Direct costs of myopia in Singapore","volume":"23","author":"Lim","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.xops.2026.101334_bib8","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101334_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101334_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/jop.2006.22.41","article-title":"Prevention of myopia progression with 0.05% atropine solution","volume":"22","author":"Lee","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101334_bib11","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101334_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2026.101334_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration atropine for myopia progression (LAMP) Study: a randomized, Double-Blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101334_bib14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-Year clinical trial of the low-concentration atropine for myopia progression (LAMP) Study: phase 2 report","volume":"127","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101334_bib15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1136\/bjophthalmol-2019-314819","article-title":"Low-dose (0.01%) atropine eye-drops to reduce progression of myopia in children: a multicentre placebo-controlled randomised trial in the UK (CHAMP-UK)-study protocol","volume":"104","author":"Azuara-Blanco","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib16","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/ceo.14148","article-title":"Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial","volume":"50","author":"Lee","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib17","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","article-title":"Atropine for the treatment of childhood myopia in India: multicentric randomized trial","volume":"128","author":"Saxena","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101334_bib18","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/OPX.0000000000000178","article-title":"Atropine slows myopia progression more in Asian than white children by meta-analysis","volume":"91","author":"Li","year":"2014","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.xops.2026.101334_bib19","first-page":"1535","article-title":"Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression","volume":"104","author":"Fu","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib20","article-title":"Interventions for myopia control in children: a living systematic review and network meta-analysis","volume":"2","author":"Lawrenson","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.xops.2026.101334_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1167\/iovs.66.12.39","article-title":"IMI-Interventions for controlling myopia onset and progression 2025","volume":"66","author":"Bullimore","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101334_bib22","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s40123-022-00572-1","article-title":"Efficacy and safety of consecutive use of 1% and 0.01% atropine for myopia control in Chinese children: the Atropine for Children and Adolescent Myopia Progression Study","volume":"11","author":"Ye","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.xops.2026.101334_bib23","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib24","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1111\/aos.15235","article-title":"Myopia progression after cessation of low-dose atropine eyedrops treatment: a two-year randomized, double-masked, placebo-controlled, cross-over trial","volume":"101","author":"Wei","year":"2023","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","article-title":"Risk factors for progressive myopia in the atropine therapy for myopia study","volume":"159","author":"Loh","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","article-title":"Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% atropine: Low-Concentration atropine for Myopia Progression Study","volume":"128","author":"Li","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101334_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","article-title":"The Association of choroidal thickening by atropine with treatment effects for myopia: two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) Study","volume":"237","author":"Yam","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2026.101334_bib28","article-title":"Analysis of factors that may affect the effect of atropine 0.01% on myopia control","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xops.2026.101334_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.xops.2026.101334_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96698-6","article-title":"Stepwise low concentration atropine for myopic control: a 10-year cohort study","volume":"11","author":"Chuang","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.xops.2026.101334_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1167\/iovs.63.1.8","article-title":"Annual incidences and progressions of myopia and high myopia in Chinese schoolchildren based on a 5-Year cohort Study","volume":"63","author":"Li","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101334_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.xops.2026.101334_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1167\/iovs.67.1.38","article-title":"Pediatric eye disease investigator group. Does past myopia progression predict future progression?","volume":"67","author":"Beaulieu","year":"2026","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2026.101334_bib34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/OPX.0000000000001883","article-title":"The limited value of prior change in predicting future progression of juvenile-onset myopia","volume":"99","author":"Mutti","year":"2022","journal-title":"Optom Vis Sci"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:24:14Z","timestamp":1792056254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2666914526002721"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101334","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stepwise Increase in Concentrations of Atropine Treatment for Myopia Control Study","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101334","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101334"}}